Samsung Bioepis' RENFLEXIS® Infliximab Biosimilar Receives Regulatory Approval in Korea
Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® – a biosimilar version of Remicade® (infliximab), also known as SB2 – for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis and plaque psoriasis. This marks the second regulatory approval for Samsung Bioepis in Korea. The MFDS approved in September 2015 Samsung Bioepis’ BRENZYS®, a biosimilar version of Enbrel® (etanercept), also known as SB4.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151204005228/en/
Christopher Hansung Ko, President & CEO of Samsung Bioepis (Photo: Business Wire)
“We look forward to the introduction of RENFLEXIS® in Korea, where patients suffering from autoimmune diseases will soon have access to an affordable, high-quality biologic treatment option,” said Christopher Hansung Ko, President & CEO of Samsung Bioepis. “With an extensive pipeline of biosimilars on the way, we will continue to leverage our strengths in product development and quality assurance to bring these life-enhancing medications to patients who need them most.”
Samsung Bioepis is solely responsible for the development of all immunology and oncology biosimilars in its pipeline, including RENFLEXIS®, as well as global clinical trials and regulatory registration in all markets worldwide for these biosimilars. As according to the commercialization agreement signed in 2013 with Merck, MSD Korea will be responsible for the marketing, sales and distribution of RENFLEXIS® in Korea.
In a 54-week Phase 3 clinical study, RENFLEXIS® showed comparable safety and equivalent efficacy to Remicade®, as evidenced in ACR20 response rate of 65.3% in the RENFLEXIS® arm versus 69.2% in the Remicade® arm. The RENFLEXIS® study randomized 584 patients with moderate to severe rheumatoid arthritis despite methotrexate therapy across 73 sites in 11 countries.
In addition to RENFLEXIS®, Samsung Bioepis has been developing two other anti-tumor necrosis factor-alpha (anti-TNF-α) investigational biosimilar candidates, the latest developments for which are as follows:
SB4 investigational biosimilar candidate referencing Enbrel
(etanercept): On November 9, 2015 at the Annual Meeting of the
American College of Rheumatology (ACR) and the Association for
Rheumatology Health Professionals (ARHP) in San Francisco, Samsung
Bioepis announced 52-week Phase 3 SB4 clinical study results that
showed comparable safety and equivalent efficacy to Enbrel®,
as evidenced in ACR20 response rate of 80.8% in the SB4 arm versus
81.5% in the Enbrel® arm. The SB4 study randomized 596
patients across 70 sites in 10 countries.
In September 2015, Korea’s MFDS approved SB4, which will be commercialized by MSD Korea as BRENZYS®. In November 2015, the European Medicines Agency (EMA) announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on SB4, marking the first time the CHMP has adopted a positive opinion on an etanercept biosimilar. If a marketing authorization is granted by the European Commission (EC), SB4 will be commercialized in the European Union (EU) as Benepali®.
SB5 investigational biosimilar candidate referencing Humira
(adalimumab): On November 10, 2015 at the ACR/ARHP Annual Meeting
in San Francisco, Samsung Bioepis announced 24-week Phase 3 clinical
study results that showed comparable safety and equivalent efficacy to
Humira®, as evidenced in ACR20 response rate of 72.5% in
the SB5 arm versus 72.0% in the Humira® arm. The study
randomized 544 patients with moderate to severe rheumatoid arthritis
despite methotrexate therapy across 52 sites in seven countries.
About Samsung Bioepis Co., Ltd.
Samsung Bioepis was established in 2012 with a mission to develop affordable, high-quality biopharmaceutical products and to provide better patient access to these life-enhancing medications. The company aims to be the world’s leading biopharmaceutical company through innovations in product development and quality assurance.
Samsung Bioepis has commercial agreements with Biogen and Merck to commercialize and distribute biosimilar products in immunology, oncology and diabetes. The products and geographic responsibilities include:
- SB4, investigational biosimilar candidate referencing Enbrel® (etanercept) – European Union, Switzerland, Japan
- SB2, investigational biosimilar candidate referencing Remicade® (infliximab) – European Union, Switzerland, Russia, Turkey
- SB5, investigational biosimilar candidate referencing Humira® (adalimumab) – European Union, Switzerland, Russia, Turkey
- SB4, investigational biosimilar candidate referencing Enbrel® (etanercept) – Worldwide, but excluding United States, European Union, Switzerland, Japan
- SB2, investigational biosimilar candidate referencing Remicade® (infliximab) – Worldwide, including United States, but excluding European Union, Switzerland, Russia, Turkey
- SB5, investigational biosimilar candidate referencing Humira® (adalimumab) – Worldwide, including United States, but excluding European Union, Switzerland, Russia, Turkey
- SB3, investigational biosimilar candidate referencing Herceptin® (trastuzumab) – Worldwide
- SB9 (MK-1293), investigational biosimilar candidate referencing Lantus® (insulin glargine) – Worldwide
Samsung Bioepis is a joint venture between Samsung Biologics and Biogen. For more information, please visit: www.samsungbioepis.com.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Universal Laser Systems® Expands Portfolio of Laser Material Processing Systems with the ULTRA Platform Series21.2.2018 18:00 | Pressemelding
ULTRA platform-based laser systems are designed and ideally suited for precision laser cutting, laser ablation, and laser surface modification in manufacturing, research and development, academic research and prototyping environments. Major features of the series include rapid, high-accuracy laser beam positioning, and the flexibility to be configured with 9.3 and 10.6 µm CO2 lasers and 1.06 µm fiber lasers. All lasers are air-cooled in a range of power from 10 to 150 watts for CO2 and 40 to 50 watts for fiber lasers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005364/en/ The ULTRA 9MW offers MultiWave processing of thin materials. (Photo: Business Wire) The variety of wavelengths and power ranges make the ULTRA platforms highly effective in the areas of organic material modification, including plastic films, industrial fabrics, engineering plastics, laminating adhesives, composite materials, and many others utilized
Luxoft One of Six Companies Collaborating with Amazon Web Services to Accelerate Blockchain Adoption21.2.2018 16:30 | Pressemelding
Luxoft Holding Inc (NYSE:LXFT), a global IT service provider, announces today that it is collaborating with Amazon Web Services (AWS) to enable corporates to adopt blockchain and Distributed Ledger Technologies (DLT). Luxoft is one of six IT and consulting services companies to make its blockchain advisory and development services available to AWS users. “We are very excited to be working with AWS to help users engage with blockchain and DLTs,” said Vasiliy Suvorov, Vice President of Technology Strategy at Luxoft. “Blockchain is about removing data silos, improving trust and operational efficiencies. By using AWS to deploy and integrate DLTs into day-to-day processes, businesses can revolutionize how they operate.” Luxoft helps accelerate the deployment and integration of blockchain and DLT-based projects on AWS and is already working on a number of DLT projects using the cloud. For example, Luxoft is building a healthcare claims processing system for a leading healthcare provider usin
Westinghouse Electric Company to Provide Engineering Support at Vandellós 1 in Partnership with EDF21.2.2018 16:30 | Pressemelding
Westinghouse Electric Company and Electricité de France (EDF), in partnership, announced today that they have been awarded a contract from Empresa Nacional de Residuos Radiactivos (ENRESA), the Spanish agency responsible for radioactive waste management and nuclear plant decommissioning. The agreement covers a four-year engineering support contract for the latency phase of the dismantling and decommissioning project at Vandellós I Nuclear Power Station in Spain and includes the preparation of technical and licensing documentation. “We are extremely pleased that ENRESA has selected Westinghouse and EDF to continue supporting the decommissioning activities at Vandellós I Nuclear Power Station,” said Yves Brachet, Westinghouse vice president, Global Decommissioning, Decontamination, Remediation and Waste Management. “This contract further demonstrates Westinghouse’s global capabilities and expertise in providing innovative decommissioning solutions.” Sylvain Granger, head of EDF's decommi
H.I.G. Europe Completes a Strategic Investment in Puerto de Indias Group21.2.2018 14:02 | Pressemelding
H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €20 billion of equity capital under management, announced that one of its affiliates has acquired a majority interest in Puerto de Indias Group (“Puerto de Indias” or the “Company”), with the goal of accelerating the Company’s growth initiatives and supporting its expansion into international markets. Headquartered in Seville, Spain, Puerto de Indias was founded by Jose Antonio and Francisco Rodriguez Fernandez, and has become in a short period of time the leading player in the Rosé Gin market in Spain. Puerto de Indias has in place an ambitious international expansion plan targeting the development of a commercial network in Europe, the U.S., and Latin America, as well as strategic alliances with strong international distributors. Leopoldo Reaño, Principal at H.I.G. Europe, commented on the transaction: “We are thrilled to have the opportunity to support the management team led by Jose Antonio an
Savi Adds Supply Chain Star Johannes Giloth to Advisory Board21.2.2018 13:02 | Pressemelding
Savi®, an innovator in big data/machine learning analytic solutions, supply chain management software, and sensor technology, today announced that Johannes Giloth has joined its board of advisers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005117/en/ Johannes Giloth (Photo: Business Wire) Giloth is a long-time leader in procurement, supply chain and manufacturing. He currently serves as Chief Procurement Officer and Senior Vice President of Operations at Nokia where he is in charge of every aspect of operations accountability worldwide — from demand planning to execution, procurement to manufacturing. “Johannes understands the impact the explosion of data will have on the supply chain. And his tremendous success as an innovative supply chain leader proves he knows what companies need to transform their supply chains,” said Rich Carlson, CEO of Savi Technology. “I’m thrilled to have him join Savi’s advisory board. As
Mavenir Unveils Its Industry First Mobile-Native UCaas Solution, Entering into a New UCC Market Category21.2.2018 13:00 | Pressemelding
Mavenir, a leader in mobile network transformation, today announced its industry first Mobile-Native Unified Communications and Collaboration as a Service (mUCaaS) solution, uniquely designed to address the specific mobility needs of SOHO and SMBs. Using mobile native wireless technologies while still supporting current communications desktop usage is a complete paradigm shift compared to traditional UCaaS offerings. Leveraging Mavenir’s expertise in mobile networks with Voice over LTE (VoLTE) and Rich Communication Services (RCS), the solution provides new recurring-revenue opportunities for mobile network operators (MNOs) while addressing the real business need for truly mobile communications for the workforce. MNOs are under pressure in the consumer market with flat growth, an intensive price war on voice and data plans, and fierce competition from OTT applications. The Enterprise market offers a better outlook with UCaaS telephony and messaging projecting growth of 15.2% CAGR1 2016